University of Birmingham Enterprise has announced a new spinout company, Viatem Ltd, to develop and exploit the therapeutic potential of PEPITEM.
The announcement coincides with the presentation of new research showing that synthetic PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) can prevent or delay the onset of rheumatoid arthritis (RA) in animal models of disease and restore regulation of white blood cell migration in human tissues.
RA is an autoimmune disease that affects over 20 million people worldwide. It results in extensive damage to joints and causes significant disability. There is currently no curative treatment.
PEPITEM is a 14 amino acid peptide, and a naturally occurring mediator in the adiponectin pathway which controls the recruitment of immune cells into inflamed tissues.
The adiponectin pathway is believed to be pivotal in protecting inflamed tissues from excessive damage, and is disordered in conditions such as rheumatoid arthritis, inflammatory bowel disease and type 1 diabetes, all of which are characterised by chronic inflammation that destroys the patient’s own tissues.
According to Dr Jonathan Watkins, head of IP at University of Birmingham Enterprise, it was the foundational nature of the science that first attracted the attention of the University’s technology transfer and commercialisation teams.
He said: “It is extremely rare that a completely new regulatory pathway is discovered, and that it is possible to modulate it through an identified target.”
Dr James Wilkie, CEO of University of Birmingham Enterprise, added: “Despite substantial innovation over the last few decades, there are still significant unmet needs in rheumatoid arthritis treatment.
“We are delighted to be commercialising this novel therapeutic target which is supported by a robust and increasing body of evidence.”
The University has licensed the technology to the newly formed spinout company Viatem Ltd.
The University is a shareholder in the company, which has received funding from Innovate UK, the West Midlands Academic Health Science Network and the University of Birmingham’s Enterprising Birmingham Fund.
Viatem is located in the BioHub Birmingham®, the University’s bioincubator, which is based at the Birmingham Research Park.
Our BQ Bulletin emails will land in your inbox at 7.30am, Monday to Friday, with a mix of the latest local business news, national news, and features to inspire you. Sign up here!
Click here to read our privacy statement